

Highlights of This Issue 2017

SPECIAL FEATURES

CCR Translations

- 2019** New Approaches but the Same Flaws in the Search for Prognostic Signatures
Ramon Salazar and Josep Taberero
See related article, p. 2159
- 2023** Emerging Immunologic Biomarkers: Setting the (TNM-Immune) Stage
Janis M. Taube
See related article, p. 2147
- 2026** SETting OP449 into the PP2A-Activating Drug Family
Paolo Neviani and Danilo Perrotti
See related article, p. 2092

CCR Perspectives in Drug Approval

- 2029** U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
Shakun M. Malik, Virginia Ellen Maher, Karen E. Bijwaard, Robert L. Becker, Lijun Zhang, Shenghui W. Tang, Pengfei Song, Qi Liu, Anshu Marathe, Brenda Gehrke, Whitney Helms, Diane Hanner, Robert Justice, and Richard Pazdur

CCR Drug Updates

- 2035** Dabrafenib and Trametinib, Alone and in Combination for *BRAF*-Mutant Metastatic Melanoma
Alexander M. Menzies and Georgina V. Long


Molecular Pathways

- 2044** Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
 Anjali Mishra, Laura Sullivan, and Michael A. Caligiuri
- 2051** Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Sara C. Meyer and Ross L. Levine

Reviews

- 2060** Molecular Biomarkers in Advanced Renal Cell Carcinoma
Pablo Maroto and Brian Rini
- 2072** Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet and Virginia Hernandez-Gea

HUMAN CANCER BIOLOGY

- 2080** High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing
 Richard Bourgon, Shan Lu, Yibing Yan, Mark R. Lackner, Weiru Wang, Victor Weigman, David Wang, Yinghui Guan, Lisa Ryner, Hartmut Koeppen, Rajesh Patel, Garret M. Hampton, Lukas C. Amler, and Yulei Wang

CANCER THERAPY: PRECLINICAL

- 2092** Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa, Christopher A. Eide, Jessica Oddo, Jeffrey W. Tyner, Rosalie Sears, Michael P. Vitek, Maria D. Odero, Dale J. Christensen, and Brian J. Druker
See related article, p. 2026
- 2104** Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs
Joseph A. Reddy, Ryan Dorton, Alicia Bloomfield, Melissa Nelson, Marilyn Vetzal, John Guan, and Christopher P. Leamon
- 2115** Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer
Philip M. Spanheimer, Jung-Min Park, Ryan W. Askeland, Mikhail V. Kulak, George W. Woodfield, James P. De Andrade, Anthony R. Cyr, Sonia L. Sugg, Alexandra Thomas, and Ronald J. Weigel

Table of Contents

IMAGING, DIAGNOSIS, PROGNOSIS

- 2126** **A Peptide-Based Positron Emission Tomography Probe for *In Vivo* Detection of Caspase Activity in Apoptotic Cells**
Matthew R. Hight, Yiu-Yin Cheung, Michael L. Nickels, Eric S. Dawson, Ping Zhao, Samir Saleh, Jason R. Buck, Dewei Tang, M. Kay Washington, Robert J. Coffey, and H. Charles Manning
- 2136** **A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential**
Yunping Qiu, Guoxiang Cai, Bingsen Zhou, Dan Li, Aihua Zhao, Guoxiang Xie, Houkai Li, Sanjun Cai, Dong Xie, Changzhi Huang, Weiting Ge, Zhanxiang Zhou, Lisa X. Xu, Weiping Jia, Shu Zheng, Yun Yen, and Wei Jia
- 2147** **Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers**
Giuseppe Di Caro, Francesca Bergomas, Fabio Grizzi, Andrea Doni, Paolo Bianchi, Alberto Malesci, Luigi Laghi, Paola Allavena, Alberto Mantovani, and Federica Marchesi
See related article, p. 2023
- 2159** **Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients**
Jeroen Dekervel, Daphne Hompes, Hannah van Malenstein, Dusan Popovic, Xavier Sagaert, Bart De Moor, Eric Van Cutsem, André D'Hoore, Chris Verslype, and Jos van Pelt
See related article, p. 2019
- 2169** **Hypermethylation of the *GABRE~miR-452~miR-224* Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy**
Helle Kristensen, Christa Haldrup, Siri Strand, Kamilla Mundbjerg, Martin M. Mortensen, Kasper Thorsen, Marie Stampe Ostensfeld, Peter J. Wild, Christian Arsov, Wolfgang Goering, Tapio Visakorpi, Lars Egevad, Johan Lindberg, Henrik Grönberg, Søren Høyer, Michael Borre, Torben F. Ørntoft, and Karina D. Sørensen
- 2182** **Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [¹⁸F]-MFBG and ¹²³I-MIBG**
Hanwen Zhang, Ruimin Huang, Nai-Kong V. Cheung, Hongfen Guo, Pat B. Zanzonico, Howard T. Thaler, Jason S. Lewis, and Ronald G. Blasberg

CANCER THERAPY: CLINICAL

- 2192** **A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors**
Eric Angevin, Josep Tabernero, Elena Elez, Steven J. Cohen, Rastilav Bahleda, Jean-Luc van Laethem, Christian Ottensmeier, Jose A. Lopez-Martin, Sally Clive, Florence Joly, Isabelle Ray-Coquard, Luc Dirix, Jean-Pascal Machiels, Neil Steven, Manjula Reddy, Brett Hall, Thomas A. Puchalski, Rajesh Bandekar, Helgi van de Velde, Brenda Tromp, Jessica Vermeulen, and Razelle Kurzrock
- 2205** **First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors**
María Elena Elez, Josep Tabernero, David Geary, Teresa Macarulla, S. Peter Kang, Carmen Kahatt, Arturo Soto-Matos Pita, Carlos Fernandez Teruel, Mariano Siguero, Martin Cullell-Young, Sergio Szyldergemajn, and Mark J. Ratain
- 2215** **Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity**
Alana A. Kennedy-Nasser, Stephanie Ku, Paul Castillo-Caro, Yasmin Hazrat, Meng-Fen Wu, Hao Liu, Jos Melenhorst, A. John Barrett, Sawa Ito, Aaron Foster, Barbara Savoldo, Eric Yvon, George Carrum, Carlos A. Ramos, Robert A. Krance, Kathryn Leung, Helen E. Heslop, Malcolm K. Brenner, and Catherine M. Bollard
- 2226** **Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia**
Marina Y. Konopleva, Roland B. Walter, Stefan H. Faderl, Elias J. Jabbour, Zhihong Zeng, Gautam Borthakur, Xuelin Huang, Tapan M. Kadia, Peter P. Ruvolo, Jennie B. Feliu, Hongbo Lu, LaKiesha Debose, Jan A. Burger, Michael Andreeff, Wenbin Liu, Keith A. Baggerly, Steven M. Kornblau, L. Austin Doyle, Elihu H. Estey, and Hagop M. Kantarjian

Table of Contents

LETTERS TO THE EDITOR

2236 Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer—Letter
Haifeng Qiu

2237 Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer—Response
Robert J.G. Cardnell and Lauren A. Byers


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a class of recurrent hotspot mutations in PIK3R1 and PIK3CA from endometrial cancer patients that are clustered at the interface between the iSH2 domain of PIK3R1 and the C2 domain of PIK3CA. Alteration of some of these crucial amino acids has been shown to be sufficient to disrupt the inhibitory contact by PIK3R1 and may represent a novel mechanism of oncogenic activation of PIK3CA. For details, see the article by Bourgon and colleagues on page 2080 of this issue.



Clinical Cancer Research

20 (8)

Clin Cancer Res 2014;20:2017-2237.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/8>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/8>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.